In a 24-week, multicenter trial from 15 countries (n = 252 chronic kidney disease patients), daprodustat (an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor) and controls (received recombinant human erythropoietin) did not markedly impact SBP and DBP. Here, EPO is linked to chronic kidney disease.